Skip to main content
. 2018 Dec 19;28(9):1429–1444. doi: 10.1093/hmg/ddy439

Figure 1.

Figure 1

Expression of FGF10 and associated targets in human and mouse lungs. (A) FGFR2 receptor and its ligand FGF10 are expressed in lungs from patients with BPD (n = 4). (Aa) FGFR2 and (Ac) FGF10 expression in remodelled pulmonary vasculature. (Ab) and (Ad) respective high magnification. Scale bar: 20 μm. (B–C) Analysis of vascular smooth muscle cell and endothelial cell markers did not show changes in Fgf10+/− versus Fgf10+/+ control lungs at E12.5, E18.5 and P3 (HOX). (Ba) qPCR analysis showed significant decrease of Fgf10 expression in Fgf10+/− versus Fgf10+/+ lungs at E12.5, E18.5, P70 and P3 HOX, n = 4 each. (Bb–Bd) Comparative expression by qPCR analysis in Fgf10+/− versus Fgf10+/+ control lungs at (b) E12.5, (c) E18.5 and (d) P3 HOX of Vegfr2, Vegfa, Pdgfrb and Pdgfb. No significant difference is observed even though a trend towards a decrease in Vegfa is observed at E18.5. (C) IF for PECAM staining on E18.5 (a,b) Fgf10+/+ and (c,d) Fgf10+/− lungs (n = 4 each) showed slightly lower immunoreactivity in Fgf10+/− lungs. Scale bar: a, c, 100 μm; b, d, 30 μm.